As the Asian markets navigate a period of uneven economic recovery, investor attention has increasingly turned to growth companies with strong insider ownership, which can signal confidence in a company's long-term prospects. In this context, identifying stocks where insiders have significant stakes could be particularly appealing for investors looking to align with leadership that is directly invested in the company's success.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name |
Insider Ownership |
Earnings Growth |
|---|---|---|
| Seojin SystemLtd (KOSDAQ:A178320) |
22% |
106.4% |
| SEERS (KOSDAQ:A458870) |
33.2% |
41.5% |
| Meitu (SEHK:1357) |
22.7% |
31.5% |
| Meiko Electronics (TSE:6787) |
19.2% |
27.9% |
| L&C BIOLTD (KOSDAQ:A290650) |
24% |
148.5% |
| HUMAN MADE (TSE:456A) |
23.9% |
22.6% |
| Great Microwave Technology (SHSE:688270) |
21.1% |
85.5% |
| Gold Circuit Electronics (TWSE:2368) |
30.2% |
38.2% |
| Fulin Precision (SZSE:300432) |
10.4% |
60.7% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) |
14.1% |
40.4% |
Let's uncover some gems from our specialized screener.
Dalian BIO-CHEM
Simply Wall St Growth Rating:★★★★★☆
Overview:Dalian BIO-CHEM Company Limited researches, develops, produces, and sells industrial fungicides in China and internationally with a market cap of CN¥13.84 billion.
Operations:Dalian BIO-CHEM generates revenue through the research, development, production, and sale of industrial fungicides both domestically and internationally.
Insider Ownership:30.8%
Dalian BIO-CHEM, despite recent volatility and a decrease in profit margins to 11.5% from 24.7%, is forecasted to experience significant earnings growth of 41.4% annually, outpacing the Chinese market's average. The company recently completed a share buyback worth CNY 50.99 million, reflecting strong insider confidence amidst high ownership levels. However, revenue for Q1 2026 dropped significantly compared to the previous year, indicating potential short-term challenges despite long-term growth prospects.
Hubei Feilihua Quartz Glass
Simply Wall St Growth Rating:★★★★★☆
Overview:Hubei Feilihua Quartz Glass Co., Ltd. specializes in the research, development, production, and sale of quartz glass and fiber, as well as composite materials both in China and internationally, with a market cap of CN¥63.57 billion.
Operations:The company generates revenue of CN¥2.23 billion from its Non-Metallic Mineral Products Industry segment.
Insider Ownership:16.2%
Hubei Feilihua Quartz Glass is forecasted to achieve significant earnings growth of 39.3% annually, surpassing the Chinese market average. Despite a volatile share price recently, its revenue and net income have shown robust increases, with Q1 2026 sales rising to CNY 621.73 million from CNY 406.26 million a year ago. The company raised nearly CNY 294 million through a private placement in May, indicating strategic financial maneuvers amidst high insider ownership levels.
Guangzhou Wondfo BiotechLtd
Simply Wall St Growth Rating:★★★★☆☆
Overview:Guangzhou Wondfo Biotech Co., Ltd is an in vitro diagnostics company involved in the research, development, production, marketing, sale, and service of diagnostic products in China with a market cap of CN¥8.84 billion.
Operations:Revenue Segments (in millions of CN¥):
Insider Ownership:33.3%
Guangzhou Wondfo Biotech is trading significantly below its estimated fair value and is expected to achieve profitability within three years, with a forecasted annual profit growth surpassing the market average. However, recent earnings show a decline, with Q1 2026 revenue at CNY 581.74 million compared to CNY 800.28 million last year, and net income dropping to CNY 84.4 million from CNY 189.14 million. Dividend coverage remains weak amidst these financial challenges.
Taking Advantage
-
Reveal the 480 hidden gems among our Fast Growing Asian Companies With High Insider Ownership screener with a single click here.
-
Interested In Other Possibilities? We've found 10 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SHSE:603360 SZSE:300395 and SZSE:300482.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
